RT Journal Article
SR Electronic
T1 Impact of Chronic Comorbidities on Progression and Prognosis in Patients with COVID-19 A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.14.20125997
DO 10.1101/2020.06.14.20125997
A1 Zeng, Hesong
A1 Zhang, Tianlu
A1 He, Xingwei
A1 Du, Yuxin
A1 Tong, Yan
A1 Wang, Xueli
A1 Zhang, Weizhong
A1 Shen, Yin
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.14.20125997.abstract
AB Background The recent outbreak of COVID-19 has rapidly spread worldwide. A large proportion of COVID-19 patients with chronic underlying complications have been reported to be in severe condition and show unpromising clinical outcomes. But whether chronic comorbidities are risk factors affecting the severity of COVID-19 has not been well described.Methods We included COVID-19 patients who had been admitted to Tongji Hospital, Tongji medical college of HUST (Wuhan, China) from January, 27, 2020 to March, 8, 2020 in this retrospective cohort study. The final date of follow-up was March, 30, 2020. All patients were diagnosed with COVID-19 according to Prevention and control Scheme for Novel Coronavirus Pneumonia published by National Health Commission of the People’s Republic of China and WHO interim. Demographic data, medical history, clinical symptoms and signs, laboratory findings, chest computed tomography (CT), treatment and clinical outcomes were extracted from electronic medical records with standardized data collection forms and compared among different groups.Results 1031 COVID-19 inpatients were included in this study, of whom 866 were discharged and 165 were dead in hospital. 73% of 165 dead patients had complicated chronic comorbidities. Of the 1031 patients, 514 (50%) were combined with chronic comorbidities, and showed CFR 2.8 times as that of patients without any underlying disease.The number of patients with hypertension accounted for three fourths of those with concomitant underlying diseases. The univariable regression revealed that patients in the simple hypertension group showed overall risk higher than those in the simple diabetes mellitus group. In the age-grouped research, patients in the hypertension senile group were proved to be at the highest risk, which might be associated with the level of LDH and eGFR. In this retrospective cohort study, 166 (43%) patients with hypertension took CCB during the hospitalization, the odds ratio of CFR in patients with hypertension taking CCB group was 0.68 (P = 0.155), compared to those not.Conclusion Our data shows that the clinical manifestations of most hospitalized patients with COVID-19 are actually systemic syndromes, although COVID-19 is defined as novel coronavirus pneumonia in China. Hypertension is not just a chronic underlying comorbidity, but also a risk factor affecting the severity of COVID-19 and does play a critical role in improving patients’ clinical outcomes. Therefore, hypertension management in patients with COVID-19 should be regarded as a major challenge in the diagnostic and therapeutic strategies, including optimal management of blood pressure and pathophysiological status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by COVID-19 Emergency Response Project of Wuhan Science and Technology Department (2020020201010018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Tongji Hospital, Wuhan, China, approved this retrospective study and written informed consent was waived (No. TJ-C20200140).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data was extracted from electronic medical records with standardized data collection forms in Tongji Hospital (Wuhan, China), which had been approved by the Research Ethics Commission of Tongji Hospital, Tongji medical college of HUST. The data used to support the findings of this study are available from the corresponding author upon request.ACIAcute cardiac injuryAKIAcute kidney injuryALTAlanine aminotransferaseAPTTActivated partial thromboplastin timeASTAspartate aminotransferaseCCBCalcium channel blockersCCIRCase-critically ill rateCDCChinese Center for Disease Control and PreventionCFRCase-fatality rateCHDCoronary atherosclerotic heart diseaseCOVID-19Coronavirus disease 2019CRPC-reactive proteinCRRTContinuous renal replacement therapyDMDiabetes mellitusECMOExtracorporeal membrane oxygenationeGFRGlomerular filtration rateESRErythrocyte sedimentation rateIL-6Interleukin 6LDHLactate dehydrogenaseLOSLength of stayMAPMean arterial pressureNT-proBNPN-terminal pro-brain natriuretic peptideOOSOximeter oxygen saturationPTProthrombin timeRASRenin-angiotensin-aldosterone systemRASIRenin-angiotensin-aldosterone system inhibitorsSARS-CoV-2IgG SARS-CoV-2 Immunoglobulin GSARS-CoV-2IgM SARS-CoV-2 Immunoglobulin MScrSerum creatinineTNITroponin IWHOWorld Health Organization